Javier Morales

Javier Morales is a Senior Research Scientist at Oxford BioTherapeutics since October 2019, with prior experience as a Research Scientist II at Eureka Therapeutics, Inc. from June 2015 to March 2019. At Eureka, Javier co-led a successful collaboration with Boehringer Ingelheim for the development of bispecific antibodies, resulting in a multimillion-dollar milestone payment and potential future royalties. Javier's foundational research work includes a Ph.D. in Biochemistry from the University of California, Santa Cruz, where the dissertation focused on developing a structure-based vaccine for HIV-1, and a Bachelor of Science in Cell Biology from the University of California, Davis.